TLGT - テリジェント (Teligent Inc.)

TLGTのニュース

   The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study  2020/09/04 11:28:02 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3) Akouos Inc (NASDAQ: AKUS ) FibroGen Inc (NASDAQ: FGEN )(reacted to an adverse clinical readout for a rival drug to treat chronic kidney disease related anemia) Generation Bio Co (NASDAQ: GBIO ) Immunovant Inc (NASDAQ: IMVT ) Sutro Biopharma Inc (NASDAQ: STRO ) ( reacted to announcement concerning presentation of positive data for ovarian cancer drug) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 3) Akebia Therapeutics Inc (NASDAQ: AKBA ) (announced negative safety results for a late-stage study of drug to treat chronic kidney disease-induced anemia) AnPac Bio-Medical Science Co Ltd – ADR (NASDAQ: ANPC ) Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC ) Eyepoint Pharmaceuticals Inc (NASDAQ: EYPT ) Genfit SA (NASDAQ: GNFT ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Homology Medicines Inc (NASDAQ: FIXX ) Immatics NV (NASDAQ: IMTX ) Interpace Biosciences Inc (NASDAQ: IDXG ) Jaguar Health Inc (NASDAQ: JAGX ) Legend Biotech Corp (NASDAQ: LEGN ) Monopar Therapeutics Inc (NASDAQ: MNPR ) NanoVibronix Inc (NASDAQ: NAOV ) Odonate Therapeutics Inc (NASDAQ: ODT ) RA Medical Systems Inc (NYSE: RMED ) Recro Pharma Inc (NASDAQ: REPH ) Rockwell Medical Inc (NASDAQ: RMTI ) Soliton Inc (NASDAQ: SOLY ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS ) Teligent Inc (NASDAQ: TLGT ) Related Link: Attention Biotech Investors: Mark Your Calendar For September PDUFA Dates Stocks In Focus Lilly Gets FDA Nod For 2 Higher Doses of Its Best-selling Diabetes Drug Eli Lilly And Co (NYSE: LLY ) said the FDA approved two additional doses of its Type 2 diabetes drug Trulicity.
   The Daily Biotech Pulse: Altimmune Reports Positive Preclinical Data For Intranasal COVID-19 Vaccine, AbbVie Licenses Morphic's Drug, Viveve Clinical Readout  2020/08/25 12:38:16 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 24) Abbott Laboratories (NYSE: ABT ) Cancer Genetics Inc (NASDAQ: CGIX ) (announced a deal to buy organoid start up company StemoniX) Cardiff Oncology Inc (NASDAQ: CRDF ) Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) Cerus Corporation (NASDAQ: CERS ) (moved on FDA's emergency use authorization for plasma therapy as a potential COVID-19 treatment) ESSA Pharma Inc (NASDAQ: EPIX ) Fortress Biotech (NASDAQ: FBIO ) Inozyme Pharma Inc (NASDAQ: INZY ) Kamada Ltd. (NASDAQ: KMD) (reacted to the news of EUA for plasma anti-COVID-19 therapy) Keros Therapeutics Inc (NASDAQ: KROS ) Lantern Pharma Inc. (NASDAQ: LTRN ) Mirati Therapeutics Inc (NASDAQ: MRTX ) Pacific Biosciences of California Inc (NASDAQ: PACB ) Principia Biopharma Inc (NASDAQ: PRNB ) Protagonist Therapeutics Inc (NASDAQ: PTGX ) Qiagen NV (NYSE: QGEN ) Revance Therapeutics Inc (NASDAQ: RVNC ) Turning Point Therapeutics Inc (NASDAQ: TPTX ) (FDA granted a third fast-track designation to its lead drug candidate, repotrectinib) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Aug. 24) Acorda Therapeutics Inc (NASDAQ: ACOR ) Alector Inc (NASDAQ: ALEC ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Gritstone Oncology Inc (NASDAQ: GRTS ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Hoth Therapeutics Inc (NASDAQ: HOTH ) Iterum Therapeutics PLC (NASDAQ: ITRM ) Kymera Therapeutics Inc (NASDAQ: KYMR ) (IPOed Friday) NanoVibronix Inc (NASDAQ: NAOV ) Neurobo Pharmaceuticals Inc (NASDAQ: NRBO ) Polypid Ltd (NASDAQ: PYPD ) Poseida Therapeutics, Inc. (NASDAQ: PSTX ) Recro Pharma Inc (NASDAQ: REPH ) Teligent Inc (NEW JERSEY) (NASDAQ: TLGT ) Tricida Inc (NASDAQ: TCDA ) (FDA rejected its drug to treat metabolic acidosis and requested additional data) Unity Biotechnology Inc (NASDAQ: UBX ) Viveve Medical Inc (NASDAQ: VIVE ) Stocks In Focus Qiagen Launches Rapid …
   Teligent Regains Compliance with NASDAQ Listing Requirements  2020/06/22 20:15:00 GlobeNewswire
BUENA, N.J., June 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic…
   SEC Uses Coronavirus As Excuse To Abandon Audit Requirement Rules For Small Companies  2020/03/22 19:00:00 Zero Hedge
SEC Uses Coronavirus As Excuse To Abandon Audit Requirement Rules For Small Companies "Never let a crisis go to waste," were the famed words of Rahm Emanuel some years back. And now, it looks like the SEC is abiding by those words. While the rest of the world faces the existential threat of the coronavirus, the Securities and Exchange Commission has spinelessly taken this opportunity to ease audit requirements on smaller companies, according to the Wall Street Journal . Those pushing for the change say it could allow smaller firms to cut costs and invest in new products and technology. The rule was approved Thursday and applies to companies with less than $700 million in annual revenue. They will no longer need to have an auditor examine their internal controls, a rule that has been in place since the days of Enron and WorldCom. What could go wrong? Also, to no one's surprise, it was also discovered that many people pushing for the rule change had "accounting problems". For example, Teligent, Inc.'s CFO wrote that the rule would give it time “to develop high quality and competitive products to treat the nation’s most dire public health concerns.” But analysis from Joe Schroeder, an accounting professor at Indiana University, found that at least 12 companies supporting the rule change had either restated earnings or had "material weaknesses" flagged by auditors during past audits.
   Teligent, Inc. Announces FDA Request for Further Data on Complex Drug | MarketScreener  2019/12/23 22:13:03 MarketScreener
BUENA, N.J., Dec. 23, 2019 -- Teligent, Inc. , a New Jersey-based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter … | December 23, 2019
   Teligent Regains Compliance with NASDAQ Listing Requirements  2020/06/22 20:15:00 GlobeNewswire
BUENA, N.J., June 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic…
   SEC Uses Coronavirus As Excuse To Abandon Audit Requirement Rules For Small Companies  2020/03/22 19:00:00 Zero Hedge
SEC Uses Coronavirus As Excuse To Abandon Audit Requirement Rules For Small Companies "Never let a crisis go to waste," were the famed words of Rahm Emanuel some years back. And now, it looks like the SEC is abiding by those words. While the rest of the world faces the existential threat of the coronavirus, the Securities and Exchange Commission has spinelessly taken this opportunity to ease audit requirements on smaller companies, according to the Wall Street Journal . Those pushing for the change say it could allow smaller firms to cut costs and invest in new products and technology. The rule was approved Thursday and applies to companies with less than $700 million in annual revenue. They will no longer need to have an auditor examine their internal controls, a rule that has been in place since the days of Enron and WorldCom. What could go wrong? Also, to no one's surprise, it was also discovered that many people pushing for the rule change had "accounting problems". For example, Teligent, Inc.'s CFO wrote that the rule would give it time “to develop high quality and competitive products to treat the nation’s most dire public health concerns.” But analysis from Joe Schroeder, an accounting professor at Indiana University, found that at least 12 companies supporting the rule change had either restated earnings or had "material weaknesses" flagged by auditors during past audits.
   Teligent, Inc. Announces FDA Request for Further Data on Complex Drug | MarketScreener  2019/12/23 22:13:03 MarketScreener
BUENA, N.J., Dec. 23, 2019 -- Teligent, Inc. , a New Jersey-based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter … | December 23, 2019
   Teligent (TLGT) Reports Q2 Loss, Tops Revenue Estimates  2019/08/05 22:15:06 Zacks Investment Research
Teligent (TLGT) delivered earnings and revenue surprises of 0.00% and 4.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering  2019/06/11 11:34:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis.
   Teligent Regains Compliance with NASDAQ Listing Requirements  2020/06/22 20:15:00 GlobeNewswire
BUENA, N.J., June 22, 2020 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT) (“Teligent” or the “Company”), a New Jersey-based specialty generic…
   SEC Uses Coronavirus As Excuse To Abandon Audit Requirement Rules For Small Companies  2020/03/22 19:00:00 Zero Hedge
SEC Uses Coronavirus As Excuse To Abandon Audit Requirement Rules For Small Companies "Never let a crisis go to waste," were the famed words of Rahm Emanuel some years back. And now, it looks like the SEC is abiding by those words. While the rest of the world faces the existential threat of the coronavirus, the Securities and Exchange Commission has spinelessly taken this opportunity to ease audit requirements on smaller companies, according to the Wall Street Journal . Those pushing for the change say it could allow smaller firms to cut costs and invest in new products and technology. The rule was approved Thursday and applies to companies with less than $700 million in annual revenue. They will no longer need to have an auditor examine their internal controls, a rule that has been in place since the days of Enron and WorldCom. What could go wrong? Also, to no one's surprise, it was also discovered that many people pushing for the rule change had "accounting problems". For example, Teligent, Inc.'s CFO wrote that the rule would give it time “to develop high quality and competitive products to treat the nation’s most dire public health concerns.” But analysis from Joe Schroeder, an accounting professor at Indiana University, found that at least 12 companies supporting the rule change had either restated earnings or had "material weaknesses" flagged by auditors during past audits.
   Teligent, Inc. Announces FDA Request for Further Data on Complex Drug | MarketScreener  2019/12/23 22:13:03 MarketScreener
BUENA, N.J., Dec. 23, 2019 -- Teligent, Inc. , a New Jersey-based specialty generic pharmaceutical company, today announced its development partner has received a Complete Response Letter … | December 23, 2019
   Teligent (TLGT) Reports Q2 Loss, Tops Revenue Estimates  2019/08/05 22:15:06 Zacks Investment Research
Teligent (TLGT) delivered earnings and revenue surprises of 0.00% and 4.36%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
   The Daily Biotech Pulse: Lilly Reports Positive Long-Term Efficacy Data For Psoriasis Drug, Provention Bio Offering  2019/06/11 11:34:08 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis.

calendar